Brief: Pliant Therapeutics Announces Positive Long-Term Data From INTEGRIS-IPF Phase 2A Trial Demonstrating Bexotegrast Was Well Tolerated At 320 Mg With Durable Improvement Shown In FVC And Across Multiple Measures

Pliant Therapeutics

30/04/2023 19:13

April 30 (Reuters) - Pliant Therapeutics Inc  PLRX.O :
    * PLIANT THERAPEUTICS ANNOUNCES POSITIVE LONG-TERM DATA FROM
THE
INTEGRIS-IPF PHASE 2A TRIAL DEMONSTRATING BEXOTEGRAST WAS WELL
TOLERATED AT 320 MG WITH DURABLE IMPROVEMENT SHOWN IN FVC AND
ACROSS MULTIPLE MEASURES
    * PLIANT THERAPEUTICS INC SAYS BEXOTEGRAST WAS WELL
TOLERATED UP
TO 40 WEEKS OF TREATMENT WITH NO DRUG-RELATED SERIOUS ADVERSE
EVENTS
    * PLIANT THERAPEUTICS INC SAYS BEACON-IPF PHASE 2B TRIAL TO
BE
INITIATED IN MID-2023
    * PLIANT THERAPEUTICS -AT WEEK 24, BEXOTEGRAST-TREATED
PATIENTS
DEMONSTRATED IMPROVEMENTS ACROSS ALL  EXPLORATORY EFFICACY
ENDPOINTS VERSUS PLACEBO

Source text for Eikon:  ID:nGNX5PdykB 
Further company coverage:  PLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))